GEN Exclusives

More »

GEN News Highlights

More »
Mar 27, 2009

La Jolla Institute to Test IVT’s Delivery Platform with Infectious Disease Candidates

  • ImmunoVaccine Technologies (IVT) signed an agreement with the La Jolla Institute for Allergy & Immunology to test the application of its DepoVax™ vaccine delivery system for influenza and arenavirus vaccines.

    The institute’s epitope-based vaccines are in preclinical research. The goal is that using DepoVax, only one vaccine dose will be required for protective immunity and that a strong cellular and humoral response is achieved.

    DepoVax uses liposomes to encapsulate a target antigen and adjuvant. The vaccine formulation also relies on a hydrophobic oil carrier. The result is a depot effect that enhances vaccine induced cell-mediated and humoral immunity, according to IVT.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?